58,95 €
58,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
29 °P sammeln
58,95 €
58,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
29 °P sammeln
Als Download kaufen
58,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
29 °P sammeln
Jetzt verschenken
58,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
29 °P sammeln
  • Format: PDF

Antibodies in Diagnosis and Therapy reviews technological development in antibody research regarding the clinical results. Clinical data is collected in an expanding number of indications. Hence, the review of clinical study results has been grouped according to the fields of oncology and of chronic and acute inflammation.

  • Geräte: PC
  • ohne Kopierschutz
  • eBook Hilfe
  • Größe: 23.67MB
Produktbeschreibung
Antibodies in Diagnosis and Therapy reviews technological development in antibody research regarding the clinical results. Clinical data is collected in an expanding number of indications. Hence, the review of clinical study results has been grouped according to the fields of oncology and of chronic and acute inflammation.

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Siegfried Matzku is head of the Department of Gene Expression and Biotechnology within Preclinical Research of Merck KGaA and he has an affiliation with the University of Karlsruhe, Faculty of Biology and Geology. He is the author of over I 00 research articles and articles in books. His research interests stem from his longstanding work at the German Cancer Research Center, Heidelberg, and he pursues those in the pharmaceutical industry: tumor biology (adhesion molecules), tumor diagnosis (immunoscintigraphy) and tumor therapy (monoclonal antibodies and recombinant antibody constructs).

Rolf A. Stabel is senior physician at the Division of Oncology, Department of Medicine and head of the Laboratory of Oncology. University Hospital Ziirich Switzerland. He is associate professor of Medical Oncology at the University of Zurich, Switzerland. He has authored over 130 research articles, the majority on the development of new therapeutic approaches to lung cancer and on the treatment of malignant lymphomas. in particular high dose chemotherapy. His main research interests developed during his training in medical oncology at the Dana Farber Cancer Institute, Boston, Massachusetts.